3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
2
Urinary Bladder Neoplasms
1
Prostatic Neoplasms
1
Lung Neoplasms
1
Hemangioma
1
Disease
1
Carcinoma, Renal Cell
1
Interventions
Dexamethasone
5
Magnetic Resonance Spectroscopy
4
Cyclophosphamide
4
Blood Specimen Collection
4
Surveys and Questionnaires
3
Prednisone
3
Melphalan
3
Lenalidomide
3
Biopsy, Fine-Needle
3
fluciclovine F-18
2
carfilzomib
2
Positron-Emission Tomography
2
Mammography
2
Injections
2
Immunohistochemistry
2
Gemcitabine
2
Cytarabine
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
weifuchun
1
vistusertib
1
venetoclax
1
technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid)
1
ricolinostat
1
pomalidomide
1
phosphoribosylformylglycinamidine synthetase
1
pembrolizumab
1
ofatumumab
1
obinutuzumab
1
lortalamine
1
irinotecan sucrosofate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Disease
×
Urine Specimen Collection
×
Clear all
NCT05151341
2025-07-24
URODX-FGFR3
Institut de Cancérologie de Lorraine
Phase NA
Completed
190 enrolled